Results pending
OCEANIC-STROKE has not reported yet — the key result lands here the moment it does.
This OCEANIC-STROKE analysis splits patients by Framingham risk category. If the benefit of factor XIa inhibition with asundexian concentrates in higher-risk patients, does that change who you would treat after a non-cardioembolic stroke or TIA?
Why the trial, key points, tables, limitations, PICO, abstract, media & sources
FXIa inhibition by asundexian in participants with non-cardioembolic stroke or transient ischemic attack by non-laboratory Framingham risk score category: outcomes in the OCEANIC-STROKE randomized, placebo-controlled trial
FXIa inhibition by asundexian in participants with non-cardioembolic stroke or transient ischemic attack by non-laboratory Framingham risk score category: outcomes in the OCEANIC-STROKE randomized, placebo-controlled trial. Presented by Mukul Sharma (Population Health Research Institute, McMaster University, Hamilton, Canada). Session: LBS.02. Late-breaking trial at AHA Scientific Sessions 2026. Results pending.
Jones et al. (2026) studied this question.